Cargando…
Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art
The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasiv...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295950/ https://www.ncbi.nlm.nih.gov/pubmed/37366796 http://dx.doi.org/10.3390/biotech12020048 |
_version_ | 1785063542413590528 |
---|---|
author | Posarelli, Matteo Romano, Davide Tucci, Davide Giannaccare, Giuseppe Scorcia, Vincenzo Taloni, Andrea Pagano, Luca Borgia, Alfredo |
author_facet | Posarelli, Matteo Romano, Davide Tucci, Davide Giannaccare, Giuseppe Scorcia, Vincenzo Taloni, Andrea Pagano, Luca Borgia, Alfredo |
author_sort | Posarelli, Matteo |
collection | PubMed |
description | The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasive procedures, such as corneal transplants. However, in the last years, regeneration therapies have emerged as a promising approach to repair the damaged ocular surface by stimulating cell proliferation and restoring the eye homeostasis and function. This article reviews the different strategies employed in ocular-surface regeneration, including cell-based therapies, growth-factor-based therapies, and tissue-engineering approaches. Dry eye and neurotrophic keratopathy diseases can be treated with nerve-growth factors to stimulate the limbal stem-cell proliferation and the corneal nerve regeneration, whereas conjunctival autograft or amniotic membrane are used in subjects with corneal limbus dysfunction, such as limbal stem-cell deficiency or pterygium. Further, new therapies are available for patients with corneal endothelium diseases to promote the expansion and migration of cells without the need of corneal keratoplasty. Finally, gene therapy is a promising new frontier of regeneration medicine that can modify the gene expression and, potentially, restore the corneal transparency by reducing fibrosis and neovascularization, as well as by stimulating stem-cell proliferation and tissue regeneration. |
format | Online Article Text |
id | pubmed-10295950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102959502023-06-28 Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art Posarelli, Matteo Romano, Davide Tucci, Davide Giannaccare, Giuseppe Scorcia, Vincenzo Taloni, Andrea Pagano, Luca Borgia, Alfredo BioTech (Basel) Review The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasive procedures, such as corneal transplants. However, in the last years, regeneration therapies have emerged as a promising approach to repair the damaged ocular surface by stimulating cell proliferation and restoring the eye homeostasis and function. This article reviews the different strategies employed in ocular-surface regeneration, including cell-based therapies, growth-factor-based therapies, and tissue-engineering approaches. Dry eye and neurotrophic keratopathy diseases can be treated with nerve-growth factors to stimulate the limbal stem-cell proliferation and the corneal nerve regeneration, whereas conjunctival autograft or amniotic membrane are used in subjects with corneal limbus dysfunction, such as limbal stem-cell deficiency or pterygium. Further, new therapies are available for patients with corneal endothelium diseases to promote the expansion and migration of cells without the need of corneal keratoplasty. Finally, gene therapy is a promising new frontier of regeneration medicine that can modify the gene expression and, potentially, restore the corneal transparency by reducing fibrosis and neovascularization, as well as by stimulating stem-cell proliferation and tissue regeneration. MDPI 2023-06-15 /pmc/articles/PMC10295950/ /pubmed/37366796 http://dx.doi.org/10.3390/biotech12020048 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Posarelli, Matteo Romano, Davide Tucci, Davide Giannaccare, Giuseppe Scorcia, Vincenzo Taloni, Andrea Pagano, Luca Borgia, Alfredo Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art |
title | Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art |
title_full | Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art |
title_fullStr | Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art |
title_full_unstemmed | Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art |
title_short | Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art |
title_sort | ocular-surface regeneration therapies for eye disorders: the state of the art |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295950/ https://www.ncbi.nlm.nih.gov/pubmed/37366796 http://dx.doi.org/10.3390/biotech12020048 |
work_keys_str_mv | AT posarellimatteo ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart AT romanodavide ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart AT tuccidavide ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart AT giannaccaregiuseppe ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart AT scorciavincenzo ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart AT taloniandrea ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart AT paganoluca ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart AT borgiaalfredo ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart |